Addiction treatment company Proniras raises $4.6M, filing shows

Proniras Corporation, a biotech company based in Seattle, raised $4.6 million in funding and is seeking nearly $8 million more, according to a recent SEC filing.

Centered around addiction treatment, Proniras’ lead candidate aims to treat patients experiencing opioid withdrawal symptoms, but it also holds potential capabilities to support neonatal abstinence syndrome, epilepsy and more.

According to Proniras, the company has received funding from various investors, including Eli Lilly and ARCH Venture Partners. It is also included in the company portfolio of Seattle’s Accelerator Life Science Partners, a firm that provides funding and resources to biotech and research organizations.

READ THE STORY at Puget Sound Business Journal »